Announcements
- Cytek Biosciences Reports First Quarter 2024 Financial Results
- Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe
- Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024
- Cytek® Biosciences Names William McCombe Chief Financial Officer
- Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions
- Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
- Cytek Biosciences to Participate in Upcoming Investor Conferences
- Cytek Biosciences to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- Cytek® Biosciences Signs Agreement with CRG and UPF to Accelerate Scientific Discoveries
- Cytek Biosciences Announces Preliminary Full Year 2023 Revenue Results
More ▼
Key statistics
On Friday, Cytek Biosciences Inc (8EQ:BER) closed at 5.85, 73.08% above the 52 week low of 3.38 set on Nov 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.75 |
---|---|
High | 6.00 |
Low | 5.75 |
Bid | 5.70 |
Offer | 6.00 |
Previous close | 5.75 |
Average volume | 0.00 |
---|---|
Shares outstanding | 131.26m |
Free float | 119.84m |
P/E (TTM) | -- |
Market cap | 813.84m USD |
EPS (TTM) | -0.0887 USD |
Data delayed at least 15 minutes, as of May 10 2024 19:08 BST.
More ▼